Conflict of interest:RT reports issued patent 9,017,697 B2: 2006 surrounding technology for targeting DCs for antigen-specific tolerance and funding from Janssen Biotech Inc. to Uniquest resulting in development and trial of DEN-181. IG, MR, SB, and KC were employees of Janssen when the study took place. HR was CEO of Dendright Pty Ltd at the time of the study. The study funders had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; preparation of the manuscript; or decision to submit the manuscript for publication.